Search Results
Your search for ,WhO matches 21062 pages
Showing 7001 - 7050Dose-Intensified Radiotherapy Not Superior to Conventional Regimen for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
A dose-intensified approach to salvage radiotherapy failed to show superiority to a conventional dose strategy in patients with biochemically recurrent prostate cancer who had undergone radical prostatectomy, according to a study presented by Pirus Ghadjar, MD, and colleagues at the 2021...
Fecal Microbiota Transplants May Help Patients With Advanced Melanoma Respond to Immunotherapy
For patients with melanoma who do not respond to treatment with immunotherapy, adjusting the composition of microorganisms in the intestines through the use of fecal transplants may aid in overcoming resistance to therapy. These findings were published by Davar et al in Science. In the study, some...
Genetic Mutations Linked to Worse B-Cell ALL Outcomes in Pediatric Hispanic and Latino Patients
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino patients, according to a new study published by Raca et al in the journal Leukemia. Researchers said a novel therapeutic drug combination—as well as testing for...
FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Bone Marrow Suppression in Adults Being Treated for SCLC
On February 12, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer (SCLC)....
Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma
Treatment with the antibody-drug conjugate enfortumab vedotin-ejfv has been found to significantly increase survival of patients with metastatic urothelial carcinoma, according to results from the phase III EV-301 clinical trial. These findings were presented by Thomas Powles, MD, PhD, and...
Update From ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Metastatic Prostate Cancer
The phase III ACIS trial met its primary endpoint at 6 months, showing that apalutamide plus abiraterone acetate/prednisone extended radiographic progression-free survival vs abiraterone acetate/prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. An ...
FDA Pipeline: Breakthrough Designations in CML and for Cachexia, EUA for COVID-19
Recently, the U.S. Food and Drug Administration (FDA) issued a Breakthrough Therapy designation to asciminib for chronic myeloid leukemia (CML); a Breakthrough Device designation to an assay designed to help select patients with cachexia for treatment with an investigational therapeutic; and an...
ASH 2021 Guidelines for Prevention and Treatment of Venous Thromboembolism in Patients With Cancer
As reported in Blood Advances by Gary H. Lyman, MD, MPH, FASCO, FRCP, and colleagues, the American Society of Hematology (ASH) has issued evidence-based guidelines intended to assist patients, clinicians, and other health-care professionals in decisions regarding the prevention and treatment of...
Implications of Delaying Surgery for Renal Cell Carcinoma During the COVID-19 Pandemic
During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma were delayed, with an unknown impact on outcomes for patients. In a retrospective study, researchers from Rutgers Cancer Institute of New Jersey explored the impact of surgical delays for these patients...
Achievement and Maintenance of MRD Negativity With Daratumumab-Containing Regimens in Patients With Relapsed or Refractory Multiple Myeloma
In an analysis of the phase III POLLUX and CASTOR trials reported in the Journal of Clinical Oncology, Avet-Loiseau et al found that the addition of daratumumab to standard therapy was associated with higher rates of—and more prolonged—measurable residual disease (MRD) negativity in patients with...
Study Links Exposure to Nighttime Artificial Lights With Possible Elevated Risk of Thyroid Cancer
People living in regions with high levels of outdoor artificial light at night may face a higher risk of developing thyroid cancer, according to a study published by Zhang et al in the journal Cancer. Link Between Nighttime Light and Cancer Risk Over the past century, nightscapes—especially in...
Expert Point of View: Lucia Masarova, MD
Lucia Masarova, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, said the updated long-term data for momelotinib show “durable efficacy and exciting outcomes” in patients with myelofibrosis, regardless of prior exposure to...
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to updates from the SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2020 American Society of Hematology...
Sitagliptin Added to Tacrolimus/Sirolimus Prophylaxis Regimen for Acute Graft-vs-Host Disease After HSCT
In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, of Indiana University School of Medicine, and colleagues, found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a...
mFOLFIRINOX or Gemcitabine/Nab-paclitaxel for Resectable Pancreatic Cancer: Improved Overall Survival?
In a phase II trial reported in JAMA Oncology, Davendra P.S. Sohal, MD, MPH, and colleagues found that neither of two perioperative chemotherapy regimens was associated with improved overall survival in patients with resectable pancreatic ductal adenocarcinoma compared with historical rates in...
FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
On February 9, the U.S. Food and Drug Administration (FDA) granted regular approval to cemiplimab-rwlc (Libtayo) for patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. The FDA also granted...
Chinese Society of Clinical Oncology and ASCO Approve First Joint Guideline for Treatment of Stage II to IVA Nasopharyngeal Carcinoma
The Chinese Society of Clinical Oncology (CSCO) and ASCO have approved a joint guideline for the treatment of stage II to IVA nasopharyngeal carcinoma.1 The guideline was drafted by a panel of Chinese and U.S. experts and provides, for the first time, a clear set of recommendations for the use of...
High-Risk Cutaneous Squamous Cell Carcinomas: The Present and Future
Cutaneous squamous cell carcinoma is the second most common type of skin cancer, with more than 1 million cases diagnosed in the United States annually.1 Historically, cutaneous squamous cell carcinoma is grouped together with basal cell carcinoma and collectively referred to as nonmelanoma skin...
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...
Expert Point of View: Shoshana Rosenberg, ScD, MPH
Shoshana Rosenberg, ScD, MPH, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, weighed in on the implications of these findings. “The study underscores the importance of addressing psychosocial health in survivorship. it targeted a particularly...
Meditation and Education Interventions May Improve Depressive Symptoms in Young Breast Cancer Survivors
A diagnosis of breast cancer and subsequent treatment may increase the risk of depression, especially among younger women with breast cancer. A new study showed that behavioral interventions—specifically mindfulness meditation and survivorship education classes—may reduce depressive symptoms, as...
Expert Point of View: William Gradishar, MD
William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...
Novel Insights Into Multiple Myeloma
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...
COVID Virus–Specific T Cells: Potential Treatment of Severe COVID-19 Infection Under Study
It may be possible to exploit T cells from healthy volunteers who have recovered from COVID-19 as a treatment for this viral infection. Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine have designed an off-the-shelf COVID virus–specific T-cell product (called...
Expert Point of View: Deepa Jagadeesh, MD, MPH
“Although some B-cell lymphomas are highly curable, this goal remains elusive for most T-cell lymphomas (TCL). Refractory and relapsed disease post induction therapy remains a major challenge in management,” said Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of...
Allogeneic Stem Cell Transplant Improves Survival in Peripheral T-Cell Lymphoma
In a large retrospective analysis of allogeneic transplant for relapsed or refractory peripheral T-cell lymphoma (PTCL), more than half the patients studied were alive at 5 years, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “In the...
Study Examines Pregnancy Outcomes in Breast Cancer Survivors
Breast cancer survivors of child-bearing age appear to have a more difficult time becoming pregnant than the general population, and when they do become pregnant, they have a higher risk of preterm labor and need for cesarean section. Fortunately, most women deliver healthy babies, but they are...
Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?
A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
Anti–PD-1 Antibody Dostarlimab Active in Mismatch Repair–Deficient Gastrointestinal Tumors
Dostarlimab, a monoclonal antibody targeting PD-1, showed antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported at the 2021 Gastrointestinal Cancers Symposium by Thierry André, MD, of Sorbonne University and Saint-Antoine...
Expert Point of View: Michael J. Overman, MD
The study’s invited discussant, Michael J. Overman, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, said the findings of the study presented by Henriksen et al1 add to a convincing body of data showing that “the use of circulating...
Predicting Postoperative Recurrence in Stage I to III Colorectal Cancer With Circulating Tumor DNA
Patients with stage I to III colorectal cancer who have a high risk for recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA proved more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Expert Point of View: Rachna T. Shroff, MD
Invited discussant of the ClarIDHy trial, Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said positive findings for ivosidenib support the notion that “biliary cancer is a perfect example of...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Capivasertib for AKT1 E17K–Mutated Metastatic Cancers: NCI-MATCH Subprotocol EAY131-Y
As reported in JAMA Oncology by Kevin Kalinsky, MD, MS, and colleagues, the NCI-MATCH trial’s phase II subprotocol EAY131-Y has shown activity of the pan-AKT inhibitor capivasertib in a range of metastatic tumors with an AKT1 E17K mutation. The phase II trial enrolled 35 evaluable adult patients...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
The Lustgarten Foundation and AACR Honor Two American Icons by Establishing New Career Development Awards
The Lustgarten Foundation and the American Association for Cancer Research (AACR) have announced two new career development awards for early-career female and underrepresented pancreatic cancer researchers, representing a commitment of the Lustgarten Foundation of up to $1.8 million. The awards...
Improvement in Patient-Reported Outcomes After Stopping Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
In the prospective LAST study reported in JAMA Oncology, Ehab Atallah, MD, and Kathryn Flynn, PhD, of the Medical College of Wisconsin, Milwaukee, and colleagues, found that stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) was associated with the...
Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer
Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describes her family history of cancer, how she has worked with her physicians for more than a decade to survive her own diagnosis, and the...
CheckMate 274: Adjuvant Nivolumab May Improve Disease-Free Survival in Patients With Muscle-Invasive Urothelial Carcinoma
Treatment with the immunotherapy nivolumab with or without cisplatin-based chemotherapy following radical surgery significantly improved disease-free survival in patients with muscle-invasive urothelial carcinoma, irrespective of their PD-L1 status, according to a study that will be presented by...
Increase in Metastatic Prostate Cancer Diagnoses in the United States After Reduction in PSA Screening
Reduced levels of screening for prostate cancer using prostate-specific antigen (PSA) testing correspond with recent increases in the diagnosis of metastatic disease in the United States, according to a study that will be presented by Vidit Sharma, MD, and colleagues at the 2021 Genitourinary...
First-Line Lorlatinib Improves Progression-Free Survival vs Crizotinib in Advanced ALK-Positive NSCLC
As reported in The New England Journal of Medicine by Alice T. Shaw, MD, PhD, Global Head of Translational Clinical Oncology at Novartis Institutes for BioMedical Research,* and colleagues, an interim analysis of the phase III CROWN trial has shown that first-line lorlatinib significantly improved...
Understanding Patients’ Needs and Preferences: Cancer Care Stakeholders Explore Barriers and Best Practices
The keynote speaker did not mince words. “I tell everyone, do not use the term age-appropriate therapy,” said Jan White, a cancer survivor and patient advocate who described her own experience with stage IV non-Hodgkin lymphoma. “Patients with cancer,” she said, “are more than their age, gender,...
Expert Point of View: Jacob Soumerai, MD
Jacob Soumerai, MD, Assistant Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center, who was not involved in this study, commented on the MURANO study findings. “MURANO is the definitive phase III trial that established venetoclax/rituximab as a standard of care for...
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with the combination of fixed-duration venetoclax/rituximab had a longer overall survival and progression-free survival at 5 years compared with those treated with bendamustine/rituximab, according to a 5-year analysis...
Janet Woodcock, MD, Named Acting FDA Commissioner
Janet Woodcock, MD, current Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA), has been named acting FDA Commissioner, according to a report published in The New York Times.1Stephen M. Hahn, MD, who had been FDA Commissioner since December 17,...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
HERO-TOGETHER: Opportunity for Health-Care Workers to Share Their Experience With COVID-19 Vaccination
HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people fare after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health-care providers everywhere have worked together to face. On the...
Five-Year Outcomes From the CheckMate 017 and 057 Trials of Nivolumab vs Docetaxel in Previously Treated Patients With NSCLC
In an analysis of the phase III CheckMate 017 and 057 trials in previously treated patients with advanced squamous (017) and nonsquamous (057) non–small cell lung cancer (NSCLC), reported in the Journal of Clinical Oncology, Hossein Borghaei, DO, MS, and colleagues found pooled 5-year overall...
Role of Twitter in Identifying Barriers to Care Among Patients With Metastatic Breast Cancer
Information shared by women with metastatic breast cancer on social media platforms like Twitter may be a timely source of data for policymakers hoping to improve care and outcomes for these patients, according to a study published by Shimkhada et al in JMIR Public Health and Surveillance. Role of...
